Compare MATV & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATV | IRWD |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.0M | 741.8M |
| IPO Year | 1996 | 2009 |
| Metric | MATV | IRWD |
|---|---|---|
| Price | $10.74 | $3.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $10.00 | $4.94 |
| AVG Volume (30 Days) | 344.4K | ★ 2.9M |
| Earning Date | 05-21-2026 | 05-26-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $4.63 | $41.42 |
| Revenue Next Year | $3.37 | $16.01 |
| P/E Ratio | ★ N/A | $22.77 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $4.34 | $0.55 |
| 52 Week High | $15.48 | $5.78 |
| Indicator | MATV | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 32.10 | 38.49 |
| Support Level | $9.95 | $3.15 |
| Resistance Level | $11.54 | $3.73 |
| Average True Range (ATR) | 0.75 | 0.38 |
| MACD | -0.39 | -0.14 |
| Stochastic Oscillator | 4.60 | 31.95 |
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.